Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5769664 | 0.89 | CHRM2 (0.73) | CHRM2ALDH1A1HTTCA12CA2 | |
| SCHEMBL4913105 | 0.87 | CHRM2 (0.77) | CHRM2ALDH1A1HTTCA12CA2 | |
| SCHEMBL10925708 | 0.85 | CHRM2 (0.80) | CHRM2ALDH1A1CA12CA2CA9 | |
| SCHEMBL5034679 | 0.85 | CHRM2 (0.81) | CHRM2ALDH1A1HTTCA12CA2 | |
| SCHEMBL4916612 | 0.85 | CHRM2 (0.81) | CHRM2ALDH1A1HTTCA12CA2 | |
| SCHEMBL4912089 | 0.85 | CHRM2 (0.81) | CHRM2ALDH1A1HTTCA12CA2 | |
| SCHEMBL20962611 | 0.85 | ALDH1A1 (0.59) | CHRM2ALDH1A1CA12CA2LMNA | |
| SCHEMBL40401 | 0.83 | CHRM2 (0.69) | CHRM2ALDH1A1HTTHPGDLMNA | |
| SCHEMBL9201570 | 0.82 | CHRM2 (0.50) | CHRM2ALDH1A1HTTCA12CA2 | |
| SCHEMBL13159608 | 0.82 | CHRM2 (0.69) | CHRM2ALDH1A1HTTCA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066664-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES, MATERIALS FOR THEIR SYNTHESIS | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
| US-20070066664-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES, MATERIALS FOR THEIR SYNTHESIS | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
| US-20070066664-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES, MATERIALS FOR THEIR SYNTHESIS | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7169932-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | PFIZER INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169932-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | PFIZER INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169932-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | PFIZER INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| EP-1739082-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | Agouron Pharmaceuticals , Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1739082-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | Agouron Pharmaceuticals , Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20050250707-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2005-11-10 | — | — | US | disclosed |
| US-6953858-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040171842-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | PFIZER INC | 2004-09-02 | — | — | US | disclosed |
| EP-1448539-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | Agouron Pharmaceuticals , Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2002100845-A1 | HV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-0120393-A1 | Herbicide-substituted phenoxypropionic-acid esters | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1984-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, PEPD, PREP | CHRM2 4867/4885ALDH1A1 2461/4885HTT 4064/4885 |
| US-20070066664-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES, MATERIALS FOR THEIR SYNTHESIS | SERPINB1, PEPD, PREP | CHRM2 4867/4885ALDH1A1 2479/4885HTT 4011/4885 |
| US-20040171842-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | SERPINB1, PEPD, PREP | CHRM2 4861/4885ALDH1A1 2184/4885HTT 4060/4885 |
| US-20050250707-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, PEPD, PREP | CHRM2 4867/4885ALDH1A1 2461/4885HTT 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.